SAN

78.05

-1.24%↓

ORNBV.FI

66.25

-0.82%↓

SAN

78.05

-1.24%↓

ORNBV.FI

66.25

-0.82%↓

SAN

78.05

-1.24%↓

ORNBV.FI

66.25

-0.82%↓

SAN

78.05

-1.24%↓

ORNBV.FI

66.25

-0.82%↓

SAN

78.05

-1.24%↓

ORNBV.FI

66.25

-0.82%↓

Search

Sartorius AG

Geschlossen

BrancheGesundheitswesen

208.6 -2.39

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

205.2

Max

213.7

Schlüsselkennzahlen

By Trading Economics

Einkommen

26M

56M

Verkäufe

-29M

899M

KGV

Branchendurchschnitt

93.504

67.147

EPS

1.21

Dividendenrendite

0.34

Gewinnspanne

6.251

Angestellte

14,242

EBITDA

-9.6M

258M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+24.47% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.34%

2.36%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.6B

15B

Vorheriger Eröffnungskurs

210.99

Vorheriger Schlusskurs

208.6

Nachrichtenstimmung

By Acuity

16%

84%

33 / 348 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Sartorius AG Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

29. Apr. 2026, 23:53 UTC

Ergebnisse

Naver Posts Weaker First-Quarter Earnings

29. Apr. 2026, 23:41 UTC

Heiße Aktien

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29. Apr. 2026, 23:55 UTC

Ergebnisse

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29. Apr. 2026, 23:54 UTC

Ergebnisse

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29. Apr. 2026, 23:52 UTC

Ergebnisse

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29. Apr. 2026, 23:51 UTC

Ergebnisse

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29. Apr. 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29. Apr. 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29. Apr. 2026, 23:24 UTC

Ergebnisse

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29. Apr. 2026, 23:24 UTC

Ergebnisse

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29. Apr. 2026, 23:24 UTC

Ergebnisse

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29. Apr. 2026, 23:24 UTC

Ergebnisse

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29. Apr. 2026, 23:22 UTC

Ergebnisse

China Longyuan 1Q Net CNY1.70B, Down 14%

29. Apr. 2026, 23:22 UTC

Ergebnisse

China Longyuan: Power Generation Down 2.9% as of End-March

29. Apr. 2026, 23:20 UTC

Ergebnisse

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29. Apr. 2026, 23:20 UTC

Ergebnisse

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29. Apr. 2026, 23:19 UTC

Ergebnisse

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29. Apr. 2026, 23:19 UTC

Ergebnisse

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29. Apr. 2026, 23:19 UTC

Ergebnisse

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29. Apr. 2026, 23:19 UTC

Ergebnisse

China Vanke 1Q Loss Narrows>000002.SZ

29. Apr. 2026, 23:18 UTC

Ergebnisse

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29. Apr. 2026, 23:17 UTC

Ergebnisse

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29. Apr. 2026, 23:15 UTC

Ergebnisse

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29. Apr. 2026, 23:15 UTC

Ergebnisse

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29. Apr. 2026, 23:13 UTC

Ergebnisse

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29. Apr. 2026, 23:12 UTC

Ergebnisse

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29. Apr. 2026, 23:11 UTC

Ergebnisse

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29. Apr. 2026, 23:11 UTC

Ergebnisse

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29. Apr. 2026, 23:04 UTC

Ergebnisse

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29. Apr. 2026, 23:04 UTC

Ergebnisse

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Peer-Vergleich

Kursveränderung

Sartorius AG Prognose

Kursziel

By TipRanks

24.47% Vorteil

12-Monats-Prognose

Durchschnitt 265 EUR  24.47%

Hoch 307 EUR

Tief 220 EUR

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Sartorius AG – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

13 ratings

8

Buy

5

Halten

0

Sell

Technischer Score

By Trading Central

227 / 232Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Neutral Evidence

Langfristig

Weak Bullish Evidence

Stimmung

By Acuity

33 / 348 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Sartorius AG

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, support and services, and live-cell imaging and analysis software; contract manufacturing and integration, membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and biolayer interferometry products. In addition, the company offers water purification systems; surface plasmon resonance; lab balances, pipette calibration, mass comparators and metrology, moisture analyzers, equipment manufacturer cells, weights and weight sets, paint mixing solutions, and weighing accessories; and process filtration. Further, the company provides bioprocess consulting and engineering, biologics testing, media and process, instrument, octet service and support, and validation services. It serves the life science research, biopharmaceutical manufacturing, pharmaceutical quality control, cell and gene therapy, and applied industries. Sartorius Aktiengesellschaft was founded in 1870 and is headquartered in Göttingen, Germany.
help-icon Live chat